NewLink awarded $25M contract for investigational Ebola Zaire vaccine
NewLink Genetics Corporation announced that the Biomedical Advanced Research and Development Authority, or BARDA, of the United States Department of Health and Human Services has issued a $24.8M contract to a subsidiary of NewLink Genetics to support the advanced development of the investigational rVSVG-ZEBOV GP, or Ebola Zaire, vaccine candidate, designated V920. The new award includes an additional $51M of contract options which may be exercised by BARDA. BARDA has previously awarded $76.8M in contracts for development of V920. The new funding is in support of manufacturing facility readiness, manufacturing process qualification activities, and additional clinical trials to support regulatory approval of the V920 vaccine.